Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CFO Sells $20,838.09 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.49, for a total transaction of $20,838.09. Following the completion of the transaction, the chief financial officer directly owned 97,024 shares of the company’s stock, valued at approximately $435,637.76. This represents a 4.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $4.69 on Friday. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The firm’s 50 day moving average is $5.06 and its 200-day moving average is $6.58. The firm has a market capitalization of $368.26 million, a price-to-earnings ratio of -3.23 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, equities research analysts forecast that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on LXEO. Chardan Capital reissued a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. JPMorgan Chase & Co. cut their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Finally, Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Institutional Trading of Lexeo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. bought a new position in shares of Lexeo Therapeutics in the 4th quarter worth $49,650,000. Paradigm Biocapital Advisors LP acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $47,299,000. Balyasny Asset Management L.P. acquired a new position in Lexeo Therapeutics in the second quarter valued at about $16,117,000. Avoro Capital Advisors LLC bought a new position in Lexeo Therapeutics during the fourth quarter worth about $32,769,000. Finally, State Street Corp boosted its holdings in Lexeo Therapeutics by 485.1% during the fourth quarter. State Street Corp now owns 3,187,722 shares of the company’s stock worth $31,654,000 after buying an additional 2,642,877 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.